

Ohio Legislative Service Commission

Office of Research and Drafting Legislative Budget Office

S.B. 260 133 rd General Assembly	Bill Analysis
	Click here for S.B. 260's Fiscal Note

Version: As Reported by Senate Health, Human Services and Medicaid

Primary Sponsor: Sen. S. Huffman

Audra Tidball, Attorney

SUMMARY

- Prohibits a physician from personally furnishing or providing an abortion-inducing drug to a pregnant woman unless the physician is physically present where and when the initial dose of the drug is consumed.
- Makes knowingly violating the prohibition a fourth degree felony for the first offense and a third degree felony for the second and subsequent offenses.

DETAILED ANALYSIS

Physical presence requirement for abortion-inducing drugs

The bill prohibits a physician from personally furnishing or providing an abortioninducing drug to a pregnant woman unless the physician is physically present at the location where and when the initial dose of the drug is consumed.¹ "Abortion-inducing drug" is defined as a drug or regimen of drugs that causes termination of a clinically diagnosable pregnancy. It includes RU-486 (mifepristone), which is regulated by federal and Ohio law for inducing abortions (see "**Background on mifepristone**," below).²

Penalties and other sanctions

Knowingly failing to comply with the prohibition described above is a fourth degree felony unless the offender has previously been convicted of violating the prohibition or other

¹ R.C. 2919.124(B).

² R.C. 2919.124(A)(1) and 2919.123; *see also* U.S. Food & Drug Administration, *Mifeprex (mifepristone) Information*, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ mifeprex-mifepristone-information.

abortion laws. In that case, it is a third degree felony.³ Additionally, if the offender is a professionally licensed person,⁴ the offender is subject to sanctioning by the offender's regulatory or licensing board.⁵

If the offender is a physician, the following also apply:

- Disciplinary action taken for a second or subsequent violation of the bill's prohibition or existing law regarding the unlawful distribution of mifepristone⁶ must include a suspension of the physician's license for at least one year;⁷
- The physician's license is automatically suspended as of the date of the second or subsequent plea or conviction related to a violation of the bill's prohibition or existing law regarding the unlawful distribution of mifepristone,⁸ and the suspension cannot be lifted through the issuance of a certificate of qualification for employment (a process under current law for lifting collateral sanctions that bar convicted individuals from employment in certain fields);⁹
- A prosecutor must promptly notify the State Medical Board regarding a licensee's second or subsequent plea or conviction related to a violation of the bill's prohibition or existing law regarding the unlawful distribution of mifepristone.¹⁰

Criminal records checks

Violation of the bill's prohibition is added to the list in current law of offenses investigated as part of a criminal records check for certain Medicaid and other providers, including direct care providers, independent providers, and waiver agencies.¹¹

No right to abortion

The bill states that its provisions must not be construed as creating or recognizing a right to abortion or affirming the lawfulness of an abortion that would otherwise be unlawful.¹²

⁵ R.C. 2919.124(E).

⁷ R.C. 4731.22(C).

¹⁰ R.C. 4731.223(B).

¹² R.C. 2919.124(D).

LSC

³ R.C. 2919.124(C) and (E).

⁴ R.C. 2919.124(A)(3), citing R.C. 2925.01, not in the bill.

⁶ R.C. 2919.123.

⁸ R.C. 4731.22(I).

⁹ R.C. 2953.25(C)(7)(d).

¹¹ R.C. 109.572(A)(3)(a).

Prescribing mifepristone

The bill removes existing references to prescribing RU-486 (mifepristone).¹³ Under Ohio law, prescribing and prescription generally refer to an order for drugs issued by a prescriber that is interpreted and dispensed by a pharmacist to an individual patient.¹⁴ It appears that the U.S. Food and Drug Administration (FDA) requires mifepristone to be dispensed in clinics, medical offices, and hospitals by or under the supervision of a certified healthcare provider.¹⁵ Accordingly, references to prescribing mifepristone are removed from Ohio law, but related references, including giving, selling, dispensing, administering, personally furnishing, and otherwise providing mifepristone, are maintained.

Background on mifepristone

Mifepristone is approved by the FDA, in a regimen with another medication called misoprostol, to end a pregnancy within 70 days of the first day of a woman's last menstrual period. The approved dosing regimen is as follows – on day one, 200 mg of mifepristone taken by mouth and, 24 to 48 hours after taking mifepristone, 800 mcg of misoprostol taken buccally (in the cheek pouch). About 7 to 14 days after taking mifepristone, a healthcare provider must conduct a follow-up evaluation of the patient.¹⁶ The current FDA protocol for mifepristone was adopted in March, 2016. Before then, Ohio physicians had to follow an earlier protocol that was more restrictive.

Action	Date
Introduced	01-21-20
Reported, S. Health, Human Services & Medicaid	02-27-20

S0260-RS-133/ks

- ¹³ R.C. 2919.123(A) and 4729.291(B).
- ¹⁴ R.C. 4729.01, not in the bill.
- ¹⁵ *Mifeprex (mifepristone) Information.*
- ¹⁶ *Mifeprex (mifepristone) Information.*